1. Home
  2. IAG vs IMVT Comparison

IAG vs IMVT Comparison

Compare IAG & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iamgold Corporation

IAG

Iamgold Corporation

HOLD

Current Price

$15.12

Market Cap

9.5B

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$39.22

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IAG
IMVT
Founded
1990
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.5B
8.0B
IPO Year
2002
2019

Fundamental Metrics

Financial Performance
Metric
IAG
IMVT
Price
$15.12
$39.22
Analyst Decision
Buy
Buy
Analyst Count
4
8
Target Price
$17.75
$33.00
AVG Volume (30 Days)
4.6M
1.4M
Earning Date
05-05-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$44.70
N/A
Revenue Next Year
$1.11
N/A
P/E Ratio
$18.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.69
$14.32
52 Week High
$24.87
$41.23

Technical Indicators

Market Signals
Indicator
IAG
IMVT
Relative Strength Index (RSI) 46.43 57.81
Support Level $14.78 $37.53
Resistance Level $15.80 $41.23
Average True Range (ATR) 0.61 1.43
MACD -0.02 -0.29
Stochastic Oscillator 43.10 47.70

Price Performance

Historical Comparison
IAG
IMVT

About IAG Iamgold Corporation

Iamgold Corp is a mid-tier gold mining company. The company operating gold mines are divided into geographic segments such as Cote Gold mine - Canada, Burkina Faso - Essakane mine, Westwood mine - Canada. The company's s non-gold mine segments are Exploration and evaluation and development, and Corporate - which includes royalty interests. The company generates the majority of its revenue from the Cote Gold mine segment.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: